The present invention demonstrates the differential sensitivity of PBLs from lung cancer patients and healthy controls to NNK-induced genetic damage. The data provide convincing evidence that the preferred CBMN assay is a robust test for detection of this sensitivity and yields results that are a good predictor of, for example, lung cancer risk. The simplicity, rapidity, and sensitivity of the CBMN test make it a valuable tool for screening and, for example, prioritizing potential cases for early detection of the disease.

El-Zein; Randa A.

Schabath; Matthew B.

Etzel; Carol J.

Lopez; Mirtha S.

Spitz; Margaret R.

The Board of Regents of the University of Texas System

Methods for assessing cancer susceptibility to carcinogens in tobacco products

A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease to production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described, including an improved oral nicotine composition and method comprising the use of nicotine together with an inhibitor of the CYP2A6 enzyme. Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as "CYP2A6" for brevity) is predictive of an individual who: (i) has a decreased risk of becoming a smoker, (ii) will smoke less if he/she becomes dependent, and/or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6-mediated activation of tobacco smoke and other procarcinogenic substrates. This invention provides diagnostic methods for predicting tobacco dependence risk and risk for cancers related to CYP2A6 substrates in an individual by analysing for the presence of a mutant genotype for human cytochrome P450 enzyme CYP2A6 in an individual, ranging from gene duplication (multiple copies of CYP2A6) to single or even no copies due to null alleles or gene deletion.

Nicogen, Inc.

Therapeutic and diagnostic methods dependent on CYP2A enzymes

Highly-ordered nanostructure arrays and methods of preparation of the highly-ordered nanostructure arrays for adsorption of pollutants are disclosed. The highly-ordered nanostructure arrays can be vertically aligned metal oxide nanotube arrays having metal-deposited carbon nanotubes within the nanostructures. The metal-deposited carbon nanotubes within the nanostructures increase the adsorption of the pollutants, as discussed in greater detail below. The highly-ordered nanostructure arrays can be included in various filters, such as cigarette filters, to adsorb carcinogens and pollutants from the tobacco smoke.

Rashidi; Alimorad

Jafari Jozani; Kheirollah

Pourkhalil; Mahnaz

Mohajeri; Mahdi

Ghorbani; Hamzeh

Rashtchi; Maryam

Highly-ordered nanostructure arrays and methods of preparation thereof

A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease the production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described, including an improved oral nicotine composition and method comprising the use of nicotine together with an inhibitor of the CYP2A6 enzyme. Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as "CYP2A6" for brevity) is predictive of an individual who: (1) has a decreased risk of becoming a smoker, (ii) will smoke less if he/she becomes dependent, and/or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6 -mediated activation of tobacco smoke and other procarcinogenic substrates. This invention provides diagnostic methods for predicting tobacco dependence risk and risk for cancers related to CYP2A6 substrates in an individual by analyzing for the presence of a mutant genotype for human cytochrome P450 enzyme CYP2A6 in an individual, ranging from gene duplication (multiple copies of CYP2A6) to single or even no copies due to null alleles or gene deletion.

carcinogenesis

− nicotine

nicotine

carcinogenesis/− nicotine

Methods for assessing cancer susceptibility to carcinogens in tobacco products

Therapeutic and diagnostic methods dependent on CYP2A enzymes

Highly-ordered nanostructure arrays and methods of preparation thereof

Therapeutic and diagnostic methods dependent on CYP2A enzymes

La base de données d'herbes médicinales la plus complète soutenue par la science